CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Bridging the Gap Between Bone Marrow Transplantation and CAR-T Cell Therapy in Hematological Cancers.
Bridging the Gap Between Bone Marrow Transplantation and CAR-T Cell Therapy in Hematological Cancers.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
骨髓移植和CAR-T 细胞疗法已成为血液系统恶性肿瘤的两种重要治疗方式,两者的作用机制和治疗角色各不相同。本章聚焦骨髓移植的发展历程及其障碍、CAR-T 细胞疗法带来的范式转变,以及进一步的整合治疗方法。鉴于两种疗法在最佳治疗时机、患者选择及开发改善治疗结局的新策略方面具有互补作用,本文对此予以强调。我们还深入探讨了细胞因子释放综合征、移植物抗宿主病和免疫抑制等挑战。未来展望包括开发协同治疗策略、完善以患者为中心的治疗,以及解决长期生活质量问题。下文的讨论旨在通过跨学科合作促进这两类疗法的衔接,从而实现更有效、个体化且可持续的癌症治疗。
Bone marrow transplantation and chimeric antigen receptor T cell therapy have become two important treatment modalities for hematological malignancies, each having different mechanisms of action and therapeutic roles. This chapter focuses on the chronological development and obstacles of bone marrow transplantation, the paradigm-shifting impact of chimeric antigen receptor T cell therapy, and further integrative approaches. The complementary roles of these modalities are emphasized given their optimal timing, selection of patients, and the development of novel strategies to improve therapeutic outcomes.
Challenges such as cytokine release syndrome, graft-versus-host disease, and immune suppression are critically scrutinized. The future perspectives highlight the development of synergistic approaches, refining patient-centered treatments, and addressing long-term quality-of-life concerns. It is with this aim that the discussion below might help bridge these modalities through interdisciplinary efforts toward more effective, personalized, and sustainable treatments for cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。